1. CONTENTS ARE CONFIDENTIAL jasonk@orbitaltherapy.com +1 508 904 3819 www.orbitaltherapy.com ORBITAL THERAPY, LLC Dedicated, self-shielded device for breast radiotherapy

2. Problem We are overdosing the patient and treating healthy tissue. Conventional equipment ONLY allows for 2 beam access when treating breast, limiting the use of any advanced radiotherapy protocols and techniques such as SRS, IMRT

3. COMPANY CONFIDENTIAL Solution Cranial Extra-cranial Reproduce what is already being done for most other cancers. Conventional equipment currently used to deliver advanced treatment to other organs but not breast. The limiting factor is the geometric rotation of the treatment machine.

4. Prone VS Supine Key Benefits of Prone: Increased separation of breast from other organs Reduced organ/patient motion due to breathing Reduced dose to lung & heart

5. No Clinical Trials for FDA 510k & CE MammoKnife TM 6MV accelerator Multileaf Collimator Rotating Couch Anti-Reflective Beam Stop Integrated Shielding Cone-beam CT Image of breast in prone position COMPANY CONFIDENTIAL

6. Self Shielded - VS - Bunker Key Benefits of Self-Shielded: Lower patient body dose of unwanted radiation Reduced cost of install – bunker can range from $1-5M Reduced time of install Simplified relocation – no tear down $2M – $2.5M machine $0 – $100K room $1M – $5M room $1M – $5M room + $2.5M - $4M machine

7. COMPANY CONFIDENTIAL Prototype Ready – Beam ON! Industrial Design Operator in room with patient Only breast in the “bunker” CAD model Drum contains 6MV accelerator, MLC Anti-reflective beam-stop Proof-of-concept Prototype built Beam turned on – no additional shielding added, operator in the same room

8. RT procedure volume growing at 7% per year* Breast cancer RT increased from 20% to 24% from 2007 to 2009* External beam accounts for 94% of all treatments* $4B radiotherapy market size ($1B breast) 3300+ centers in US & EU A 5% market share = 50 units = $125M in sales Large Market Opportunity *Source: IMV Reports 2008 & 2010

9. 180 Centers in France / 1200 + in Europe

10. COMPANY CONFIDENTIAL Profitable in Yr 4 after Series A

11. Founders Jason Koshnitsky - CEO  20 years of experience in the area of radiation oncology & radiology  Held Sr. Management roles in American and European companies; Guidant, Philips  Co-founder of Bioropa, an internet portal for life science products  Lived in Italy, Belgium, Ukraine, Germany and Netherlands  B.S. in Medical Physics from State University of New York ESC  M.B.A. from SDA Bocconi (Milan, Italy)  2 patents issued, several pending Alan Sliski - CTO  20 years of experience in radiotherapy device business  Co-founder of Photoelectron Corp – acquired by Zeiss  Co-founder of Still River Systems, a proton radiation therapy start-up  B.S. in physics from the University of Massachusetts in Amherst  28 patents issued, several pending and many publications in various fields

12. Interest in France COMPANY CONFIDENTIAL Very attractive (best) R&D tax credit: spend €10M, receive € 5M credit First time entrants, the applicable rate is : - 50% of the R&D expenditures the first year; - 40% of the R&D expenditures the second year. Proximity to: key suppliers (Seimens, Elekta), manufacturers, customers

13. Interest in YEi COMPANY CONFIDENTIAL Visited Paris and Lyon twice in last 18 months Meetings with: Venture Capitalist firms Hospitals/Physicians Economic development agency (Thierry de Lumley) Tax credit consultants